LOS ANGELES, May 14, 2014 (GLOBE NEWSWIRE) -- Capricor Therapeutics, Inc. (OTCBB:CAPR), a biotechnology company focused on developing novel therapeutics to prevent and treat heart disease, today announced that Company management will hold a conference call to discuss first quarter 2014 business highlights on Thursday, May 15, 2014, at 4:30 p.m. ET.
On the call, Dr. Linda Marbán, Chief Executive Officer, will review Capricor's recent accomplishments, provide an update on the clinical development program of the Company's lead product candidate, CAP-1002, and discuss other Company updates.
To access the call, please dial 1-877-407-4018 in the United States and 1-201-689-8471 internationally. The conference ID number for both is 13582990. A live webcast of the conference call will also be available on the Investors page of the Company's corporate website at http://www.capricor.com. Following the live webcast, an archive of the event will be available for at least 30 days from the date posted.
In addition, a telephonic replay of the call will be available until May 29, 2014. The replay dial-in numbers are 1-877-870-5176 for domestic callers and 1-858-384-5517 internationally. Please use event passcode 13582990.
About Capricor Therapeutics
Capricor Therapeutics, Inc. (CAPR), a publicly traded biotechnology company, is focused on the development of novel therapeutics to prevent and treat heart disease. The Company has two leading product candidates: CAP-1002 and Cenderitide. The Company was formed through the November 2013 merger between Capricor, Inc., a privately held company whose mission is to improve the treatment of heart disease by commercializing cardiac stem cell therapies for patients, and Nile Therapeutics, Inc., a clinical-stage biopharmaceutical company developing innovative products for the treatment of cardiovascular diseases. Capricor Therapeutics' stock began trading under the symbol "CAPR" December 20, 2013. For additional information visit www.capricor.com.
CAP-1002, Capricor's lead product candidate, is a proprietary allogeneic adult stem cell therapy for the treatment of heart disease. The product is derived from donor heart tissue. The cells are expanded in the laboratory using a specialized process and then introduced directly into a patient's heart via infusion into a coronary artery using standard cardiac catheterization techniques.
CAP-1002 is currently not an approved product and is strictly for investigational purposes.
CONTACT: Capricor Therapeutics, Inc. AJ Bergmann, VP of Finance +1-310-358-3200 firstname.lastname@example.org The Ruth Group Lee Roth (investors) email@example.com (646) 536-7012 Kirsten Thomas (media) firstname.lastname@example.org (646) 536-7014Source: Capricor Therapeutics